WO1986003199A1 - Amino-salicylic acid derivatives and pharmaceutical compositions - Google Patents

Amino-salicylic acid derivatives and pharmaceutical compositions Download PDF

Info

Publication number
WO1986003199A1
WO1986003199A1 PCT/EP1985/000645 EP8500645W WO8603199A1 WO 1986003199 A1 WO1986003199 A1 WO 1986003199A1 EP 8500645 W EP8500645 W EP 8500645W WO 8603199 A1 WO8603199 A1 WO 8603199A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
hydroxy
benzoic acid
formula
chain
Prior art date
Application number
PCT/EP1985/000645
Other languages
French (fr)
Inventor
Giancarlo Sportoletti
Original Assignee
Italfarmaco S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco S.P.A. filed Critical Italfarmaco S.P.A.
Publication of WO1986003199A1 publication Critical patent/WO1986003199A1/en
Priority to DK346486A priority Critical patent/DK346486A/en
Priority to KR1019860700507A priority patent/KR870700608A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid

Definitions

  • the present invention refers to (5-amino-2-hydro- xy)benzoic acid derivatives having formula I
  • B ⁇ is the. imidazolium or C- or N-substituted imidazolium cation, lysine or similar basic aminoacids or methyl- glucamine;
  • R represents:
  • n is an integer from 1 to 10 and R and R , which may be the same or different, are H, halogens, is hydrogen or C -C lower alkyl; - a chain of formula:
  • m is an integer from 0 to 20 and Het is an op ⁇ tionally substituted 5- or 6-membered heterocyclic group containing one or more N, 0 or S atoms such as pyrrole, pyridine, furan, pyran, thiophene, oxazole, isoxazole, imidazole, pyrazole, thiazole groups ⁇ - a chain of formula:
  • p is an integer from 0 to 16;
  • q is an integer from 1 to 16;
  • ary ' l or aralkyl residue such as phenyl; phenyl sub ⁇ stituted by one or more fluorine or chlorine atoms, fluoroalkyl, alkoxy, alkoxycarbonyl, C -C lower alkyl, amino, dialkylamino, hydroxy, cyano groups or by groups of formula NHCOR wherein R has the above defined mean ⁇ ings; diphenyl; naphtyl groups;
  • R_, R_ and R which may be the same or diffe- 5 6 7 rent, are H, OR (R having the above defined meanings), NH , NHCOR , chlorine or fluorine atoms, fluoroalkyl groups;
  • R is hydrogen, lower alkyl, fluorine or fluoro- 8 alkyl
  • R 3 wherein R and n have the above defined meanings, n" is an integer from 1 to 10 and X and Y are an oxygen, ni ⁇ trogen, sulphur atom or a CH group;
  • r is an integer from 1 to 3 and R has the above defined meanings;
  • Another object of the invention is provided by a process for the preparation of the compounds I as well as by pharmaceutical compositions containing them as the active principle.
  • the acids 5-(2,4-dichlorobenzoylamino)-2-hydroxy benzoic, 5-(cyclohexylmethylamino)-2-hydroxy benzoic, 5-(linoleylamin ' o)-2-hydroxy benzoic, 5-(arachidylami.no)- 2-hydroxy benzoic, 5-(arachidonylamino)-2-hydroxy benzoic, 5-(2,6 or 3,5-difluoro-phenyl)-2-hydroxy benzoic, 5-(4-cy- clohexyl-butanoylamino)-2-hydroxy benzoic, 5-/2-(3-pyri- dyl)acetylamino7-2-hydroxy benzoic, 5- 4-(phenyl)benzoyl- aminq/-2-hydroxy benzoic, 5-(m-trifluoromethyl-cinnamo
  • the preparation of the compounds of the invention is carried out starting from 5-amino-salicylic acid, whi- ch, in the presence of a suitable base (pyridine, triethy- la ine etc.), optionally diluted in a suitable solvent, is treated with equimolar amounts of an activate derivative, such as the acyl chloride or anhydride, of an acid of formula RCOOH wherein R has the above defined meanings.
  • a suitable base pyridine, triethy- la ine etc.
  • an activate derivative such as the acyl chloride or anhydride
  • RCOOH an acid of formula RCOOH
  • Said method is characterized by treating the acyl derivatives mixture, recovered from the reaction medium and dissolved in suitable solvent, with catalytic amounts of imidazole base in the presence of minor amounts of water. After stirring at room temperature, for different times according to the considered acyl group, the recovery of the N-acyl derivative is carried out by solvent evapo ⁇ ration and subsequent recrystallization from a suitable solvent.
  • the imidazole or substituted imidazole salts, as well as the pharmacologically acceptable metals or other organic bases salts are prepared by mixing in a suitable solvent equimolar amounts of the corresponding acid and base. The recovery of the salt is carried out either by spontaneous precipitation from the reaction medium or by solvent evaporation under vacuum or by addition to the medium itself of a miscible precipitating solvent.
  • EXAMPLE 2 • 2) 5-Hexadecanoylamino-2-hydroxy benzoic acid 15.31 Grams (0.1 mole) of 5-amino-salicylic acid are dissolved in 300 ml of anhydrous py idine. After cool ⁇ ing to 0°C, under nitrogen and in the dark, 41.23 g (0.15 moles) of hexadecanoyl chloride are slowly added under stirring. When the addition is over, stirring is continued for 3 hours, - the mixture is poured in 100 ml of water-ice and then extracted with ethyl acetate. The organic phase is washed with diluted hydrochloric acid, water and the solvent is evaporated under reduced pressure.
  • the residue is taken up with 100 ml of acetone and 10 ml of water, 0.68 g of imidazole base are added and the mixture is stirred overnight. After solvent evaporation under reduced pressure, the residue is treated with ethyl acetate. The organic phase is washed with water, diluted hydrochloric acid- and water to neutrality. After drying on sodium sul- phate and filtration, the solvent is evaporated under vacuum. The residue is crystallized from ethanol/water. Yield: 28 g (72%) .
  • 26- 2-hydroxy-5-( 4-phenyl-benzoyl)-amino benzoic acid m.p. : 178-180°C
  • I.R. 3520, 3260, 1680, 1640, 1530, 1300;
  • This assay allows to show the presence of an inhi ⁇ bitory activity on soy lipoxygenase considered as a model of the human enzyme.
  • this enzymatic system promotes the arachidonic acid transformatipn in leukotrie- nes A4 and B4.
  • These compounds are indicated to be funda ⁇ mentally responsible for the flogosis.
  • the leuko- trienes A4 and B4 show a relevant pro-inflammatory acti ⁇ vity in the bowel1 inflammatory disease and in the Crohn' disease.
  • the inhibition activity was evaluated as ED50 (in mM) , i.e. the dose which antagonizes 50% of the aggregat ⁇ ing effect of arachidonic acid.
  • the thromboxane A2 production was measured by a bioassay test according to Moncada et al. (Moncada S., Ferreira S.H., Vane J.R. - Adv. Prost. & Thromboxanes Res. - Frolich J.C. Ed., Vol. 5, 211, 1978 - Raven Press). At scheduled times after the addition of arachidonic acid, 200 ul of P.R.P. was bioassayed for the TXA2 production and prostaglandin-like activity, on a tissue ' sequence (cascade), composed of a spiral strip of rabbit aorta and a stomach fundus strip of rat.
  • a tissue ' sequence cascade
  • the inhibition activity of the tested compounds on TXA2 production was evaluated as ED50 (in M) , i.e. the concentration able to decrease the contracturant effects of TXA2 on tissues.
  • the tested compounds were dissolved in Tween 80 and added to the P.R.P. at increasing concentrations, until the determination of the ED50 was achieved.
  • Table 3 as not limiting example, the results obtained using some of the compounds of the invention are reported.
  • the test has been performed according to Di Rosa et al. (Di Rosa M. , Giround J.P., Willoughby D.A. - J. Path. Bact., vol. 104, 15, 1971).
  • a 1% solution (0.15 ml) of carrageenin in 0.9% NaCl was injected into the pleural cavity of Sprague-Dawley rats, weighing about 250 g.
  • the animals were sacrificed, the pleural exudate volumes were measured and the leukocytes total number was counted by a micro- cell-counter, being the cavity rinsed by 0.5 ml of a sali- ne medium.
  • the % inhibition of leukocytes total number was calcu ⁇ lated versus control animals.
  • the assayed compounds were administered orally, 1 mM/kg, 30' before the carrageenin injection in the pleural cavity.
  • Table IV as not limi ⁇ ting example, the results obtained with some of the compo ⁇ unds of the invention are reported.
  • the assay has been performed according to Gemmel et al. (Gemmel D.K. Cottney J., Lewis A.J. - Agents Actions, vol. 9, 107, 1979). 1 Ml of a rabbit anti-bovine-albumin serum (freeze-dried antibodies, dissolved in 2 ml of 0.9% NaCl) was injected into the caudal vena of Sprague-Dawley male rats.
  • bovine albumin in 0.1 ml sali ⁇ ne was injected in the subplantar paw.
  • the volume of the paw was measured 5 hours later, by a mercury plethysmome- ter.
  • the tested compounds were orally administered 3 hours before the bovine albumin treatment.
  • the % inhibition of the rat foot volume increase was calculated in confront to the increase of the foot volume of untreated animals. The results obtained with some of the compounds of the inven ⁇ tion are reported in Table 5.
  • the numbers in parenthesis indicate the administered dose in mg/kg.
  • the assay has been performed according to Sharon (Sharon P., Stenson W.F. - Gastroenterology, vol. 88, 55, 1985) .
  • the administered doses (via intra-bowel, during the bowel ligature and the local injection of the acetic acid) were 0.5 mM/kg, for all the tested compounds, dispersed" in carboxymethylcellulose. The % reduction of the ulceration index has been calculated versus untreated animals.
  • the compounds of Table 1 have been subjected to the acute toxicity test in mice, by the oral route, in carbo ⁇ xymethylcellulose suspensions. All the LD proved to be higher than 1600 mg/kg.
  • the present invention refers also to all the indu ⁇ strial applicable aspects connected with the use of the compounds I and of the corresponding free acids as thera ⁇ Commissionic agents.
  • An essential aspect, of the invention is therefore provided by pharmaceutical compositions contain ⁇ ing, as the active principle, predetermined and therapeu- tically effective amounts of at least one of the above compounds in addition to conventional excipients and/or carriers.
  • the compositions of the Invention can be administered by the oral, parenteral, rectal or topical route, for instance in form of tablets, capsules, syrups, sachets, solutions, vials, bottles, suppositories.
  • the doses will be dependent on the patient's weight, age and conditions and will be anyhow ranging from 50 to 1000 mg, from 1 to 4 times a day.

Abstract

(5-Acylamino-2-hydroxy)benzoic acid and salts thereof with imidazole, substituted imidazole, lysine or methyl-glucamine are endowed with remarkable antiinflammatory, antiaggregating and antithrombotic properties.

Description

Amino-Salicylic acid derivatives and pharmaceutical compositions
The present invention refers to (5-amino-2-hydro- xy)benzoic acid derivatives having formula I
Figure imgf000003_0001
wherein: B^ is the. imidazolium or C- or N-substituted imidazolium cation, lysine or similar basic aminoacids or methyl- glucamine; R represents:
- hydrogen or a linear C -C alkyl chain, optionally substituted by one or more chlorine or fluorine atoms, free, etherified or esterified hydroxy groups, carboxy, carboxyalkyl, aminocarbonyl or N-substituted aminocarbo- nyl groups, one or more of the -CH - groups being optio¬ nally substituted by keto groups; - a chain of formula:
Figure imgf000003_0002
wherein n is an integer from 1 to 10 and R and R , which may be the same or different, are H, halogens, is hydrogen or C -C
Figure imgf000004_0001
lower alkyl; - a chain of formula:
-(CH_) -Het 2 m wherein m is an integer from 0 to 20 and Het is an op¬ tionally substituted 5- or 6-membered heterocyclic group containing one or more N, 0 or S atoms such as pyrrole, pyridine, furan, pyran, thiophene, oxazole, isoxazole, imidazole, pyrazole, thiazole groups^ - a chain of formula:
Figure imgf000004_0002
wherein p is an integer from 0 to 16;
- a chain of-formula:
Figure imgf000004_0003
wherein q is an integer from 1 to 16;
- an ary'l or aralkyl residue such as phenyl; phenyl sub¬ stituted by one or more fluorine or chlorine atoms, fluoroalkyl, alkoxy, alkoxycarbonyl, C -C lower alkyl, amino, dialkylamino, hydroxy, cyano groups or by groups of formula NHCOR wherein R has the above defined mean¬ ings; diphenyl; naphtyl groups;
- a chain of formula:
Figure imgf000005_0001
wherein m has the above defined meanings and R is hy¬ drogen or a linear or branched, saturated or unsaturat- ed, C -C alkyl group; - a chain of the formula:
Figure imgf000005_0002
wherein R_, R_ and R , which may be the same or diffe- 5 6 7 rent, are H, OR (R having the above defined meanings), NH , NHCOR , chlorine or fluorine atoms, fluoroalkyl groups;
- a chain of formula:
Figure imgf000005_0003
wherein R is hydrogen, lower alkyl, fluorine or fluoro- 8 alkyl;
- a linear or branched chain of the formula:
-(CH2_)n-X-CrH-(CH2_)n,1-Y-
R3 wherein R and n have the above defined meanings, n" is an integer from 1 to 10 and X and Y are an oxygen, ni¬ trogen, sulphur atom or a CH group;
- a chain of formula:
-(CH ) -S-R. 2 r 3 wherein r is an integer from 1 to 3 and R has the above defined meanings;
- an aminoacid residue, namely L-leucyl, of or "-L-glu- tamyl- in a free form or protected with the conventional amine protecting group, such as BOC; - an Arg-Pro-D(Phe) chain or the like;
- an uronic residues of formula:
Figure imgf000006_0001
Another object of the invention is provided by a process for the preparation of the compounds I as well as by pharmaceutical compositions containing them as the active principle. The acids 5-(2,4-dichlorobenzoylamino)-2-hydroxy benzoic, 5-(cyclohexylmethylamino)-2-hydroxy benzoic, 5-(linoleylamin'o)-2-hydroxy benzoic, 5-(arachidylami.no)- 2-hydroxy benzoic, 5-(arachidonylamino)-2-hydroxy benzoic, 5-(2,6 or 3,5-difluoro-phenyl)-2-hydroxy benzoic, 5-(4-cy- clohexyl-butanoylamino)-2-hydroxy benzoic, 5-/2-(3-pyri- dyl)acetylamino7-2-hydroxy benzoic, 5- 4-(phenyl)benzoyl- aminq/-2-hydroxy benzoic, 5-(m-trifluoromethyl-cinnamo- yl)-amino-2-hydroxy benzoic, 5- 8-(1-imidazolyl)-octano- yl7amino-2-hydroxy benzoic are per se new and are therefo- re comprised within the scope of the present invention, as well as the salts thereof with pharmacologically accepta¬ ble organic or inorganic bases and the pharmaceutical compositions containing them.
On the other hand, while the imidazole salts I are of course new, some of the corresponding acids (the anio- nic component) are known, for instance from EP-A-45955, Ger. Offen. No. 2,031,227, 2,919,545, 2,920,292, Japan Kokai No. 78-9651, Biochem. Biophys. Res. Commun. V. 101, 258, 1981 and Bio ed. Mass Spectrom. 11, 539, 1984: no pharmacological activity thereof has been however describ¬ ed.
It has now been found that also these known compo¬ unds are endowed with surprising and advantageous pharma¬ cological properties. A further object of the invention is therefore provided by pharmaceutical compositions containing as the active principle said known acids, which will be herein¬ after specifically defined.
The preparation of the compounds of the invention is carried out starting from 5-amino-salicylic acid, whi- ch, in the presence of a suitable base (pyridine, triethy- la ine etc.), optionally diluted in a suitable solvent, is treated with equimolar amounts of an activate derivative, such as the acyl chloride or anhydride, of an acid of formula RCOOH wherein R has the above defined meanings. After stirring at the room temperature or under heating, a mixture of N,0-diacyl and of N-acyl product is usually obtained w'- ich is subjected to selective hydrolysis of the 0-acyl group in extremely mild conditions so as to respect both the N-acyl group and the nature of the acyl group itself. Said method is characterized by treating the acyl derivatives mixture, recovered from the reaction medium and dissolved in suitable solvent, with catalytic amounts of imidazole base in the presence of minor amounts of water. After stirring at room temperature, for different times according to the considered acyl group, the recovery of the N-acyl derivative is carried out by solvent evapo¬ ration and subsequent recrystallization from a suitable solvent. The imidazole or substituted imidazole salts, as well as the pharmacologically acceptable metals or other organic bases salts, are prepared by mixing in a suitable solvent equimolar amounts of the corresponding acid and base. The recovery of the salt is carried out either by spontaneous precipitation from the reaction medium or by solvent evaporation under vacuum or by addition to the medium itself of a miscible precipitating solvent.
The following examples further illustrate the in¬ vention, without limiting the scope thereof. * EXAMPLE 1
1) 5-(2,4-Dichlorobenzoylaιτιino)-2-hydroxy-benzoic acid
20.95 Grams (0.1 mole) of 2,4-dichlorobenzoyl-chlo- ride are slowly added to a solution of 15.31 g (0.1 mole) of 5-amino-salicylic acid in 150 ml of anhydrous pyridine under stirring, in the dark and in nitrogen atmosphere. The solution is then poured in water-ice, filtered under reduce pressure and the obtained precipitate is washed with water to neutrality and dissolved in humid methanol.0.5 Grams of imidazole base are then added, and the mixture is stirred at the room temperature for 3 hours. The solvent is distilled off under vacuum and the residue is taken up with ethyl acetate,- washed with acidic H O (HCl) then with water to neutrality and dried on sodium sulphate. After solvent's evaporation, the residue is crystallized from methanol, yielding 17.49 g (53,63%), m.p. 233-235°C; I.R.: elemental analysis, found (calc): C = 51.74 (51.55); H = 2.85 (2.78) ; N = 4.21 (4.29) . la) Imidazole salt
10 Grams (30.66 m oles) of the product 1 are dis- solved in 100 ml of methanol and added with 2.09 g (30.66 mmoles) of imidazole. The mixture is stirred for 3 hours and the solvent is then removed under reduced pressure. The residue is crystallized from methanol-water. 10.65 Grams of la are obtained (88.11%) having a melting point of 87-89°C; I.R. : 3140, 1650, 1585, 1320 cm"1; U.V. : 233, 253, 325 nm; elemental analysis, found (calc): C = 50.83 (51.80); H = 3.47 (3.23); N = 10.72 (10.66).
EXAMPLE 2 • 2) 5-Hexadecanoylamino-2-hydroxy benzoic acid 15.31 Grams (0.1 mole) of 5-amino-salicylic acid are dissolved in 300 ml of anhydrous py idine. After cool¬ ing to 0°C, under nitrogen and in the dark, 41.23 g (0.15 moles) of hexadecanoyl chloride are slowly added under stirring. When the addition is over, stirring is continued for 3 hours, - the mixture is poured in 100 ml of water-ice and then extracted with ethyl acetate. The organic phase is washed with diluted hydrochloric acid, water and the solvent is evaporated under reduced pressure. The residue is taken up with 100 ml of acetone and 10 ml of water, 0.68 g of imidazole base are added and the mixture is stirred overnight. After solvent evaporation under reduced pressure, the residue is treated with ethyl acetate. The organic phase is washed with water, diluted hydrochloric acid- and water to neutrality. After drying on sodium sul- phate and filtration, the solvent is evaporated under vacuum. The residue is crystallized from ethanol/water. Yield: 28 g (72%) .
The product melts at 185-187°C; I.R. : 3500, 3290, 1680, 1650, 1540, 1310 cm" ; U.V.: 223, 250, 325 nm; ele- mental analysis, found (calc): C = 70.13 (70.55); H = 9.41 (9.52) ; N = 3.42 (3.58) . 2a) Imidazole salt
11.74 Grams (30 mmoles) of the compound obtained in 2 are dissolved in 100 ml of acetone and added with 2.04 g (30 mmoles) of imidazole base. After stirring at room temperature for 5 hours, the solvent is evaporated under reduced pressure and the residue is crystallized from methanol-water.
11.35 Grams (82.34%) are obtained. M.p. 132-134°C; I.-R.: 3310, 1650, 1525, 1300 cm" ; U.V. : 233, 253, 325 nm; elemental analysis, found (calc): C = 67.58 (67.95); H = 8.78 (8.99) ; N = 8.82 (9.14) .
EXAMPLES 3-23 Using the same methods above described, starting from the suitable acyl derivatives, the compounds reported in the following table were prepared.
The integers followed by an a) designate the imida¬ zole salts while the free acids are designated by progres¬ sive integers. The melting points are in °C and the I.R. values are in cm . All the compounds have elemental ana¬ lysis in agreement with the calculated values.
Figure imgf000011_0001
Figure imgf000012_0001
- continued - TABLE 1 (follows)
Figure imgf000013_0001
(*) Known from E.P. 45,955; r * * \ " " Biochem. Biophys. Res. Commun.-v.101, 258, 1981;
Ger. Offen. 2-031-227; ****** " Biomed. Mass Spectrom, v. 11, 539, 1984. EXAMPLES 24-28 According to the same methods of the previous cla¬ ims, the following 5-acyloyl-amino-salicylic acids were prepared (I.R. values in cm .and elemental analysis in agreement) :
24- 2-hydroxy-5-( 4-cyclohexyl-butanoyl)-amino benzoic acid; m.p. : 196-198°C; I.R.: 3500, 3250, 1680, 1650, 1540, 1310;
25- 2-hydroxy-5-(2-(3-pyridyl)-acetyl)-amino benzoic acid; m.p. : 221-223°C; I.R.: 3510, 3260, 1680, 1640, 1540, 1300;
26- 2-hydroxy-5-( 4-phenyl-benzoyl)-amino benzoic acid; m.p. : 178-180°C; I.R.: 3520, 3260, 1680, 1640, 1530, 1300;
27- 2-hydroxy-5-(m-trifluoromethyl-cinnamoyl) -amino benzoic acid; m.p. : 162-168°C; I.R.: 3500, 3250, 1660, 1635, 1500, 1300; 28- 2-hydroxy-5-( 8-( 1-imidazolyl)-octanoyl ) -amino ben- zoic acid; m.p. : 183-186°C; I.R.: 3510, 3260, 1680, 1635, 1510, 1300. The corresponding imidazolium salts as well as other pharmaceutically acceptable salts of the above com- pounds are prepared according to the above described me¬ thods. BIOLOGICAL ACTIVITIES
The hereinabove mentioned compounds have been te¬ sted on in vitro and in vivo assays, with the aim of giv- ing evidence to their potential biological activities. Soy lipoxygenase inhibition activity
This assay allows to show the presence of an inhi¬ bitory activity on soy lipoxygenase considered as a model of the human enzyme. In mammals, this enzymatic system promotes the arachidonic acid transformatipn in leukotrie- nes A4 and B4. These compounds are indicated to be funda¬ mentally responsible for the flogosis. Namely, the leuko- trienes A4 and B4, show a relevant pro-inflammatory acti¬ vity in the bowel1 inflammatory disease and in the Crohn' disease.
The soy lipoxygenase (E.C. 1.13.11.12), has been tested according to the method of Axelrod et al. (Axelrod B. - Cheesbrough T.H., Laakso S. in Methods in Enzymology, vol. 71, pag. 441, 1981 - Academic Press N.Y.), in the presence and in-the-absence of the—products to be assayed, using nordihydroguaiaretic acid as test reference, at room temperature.
In Table 2, as not limiting example, the results obtained with the compounds 1, la to 18, 18a are shown. In this and in the following tables, as in Table 2, the integers designate the free acids while the integers followed by the letter a relate to the corresponding imi¬ dazolium salts.
TABLE 2
Figure imgf000015_0001
- continued - TABLE 2 ( follows )
Compound Inhibition (%) Concentration (Mxl0~6)
13 14 150
13a 22 150
14 42 75
14a 78 75
15 24 150
15a 38 150
16 35 150
16a 51 150
17 26 150
17a - 42 150
18 50 250
18a 82 250
Activity on platelet aggregation and thromboxane A2 pro¬ duction Measurements were carried out on in vitro tests with citrated platelet-rich plasma (P.R.P.), obtained from New-Zealand rabbits. Platelet aggregation was carried out according to the method of Born (Born G.V.R. - Nature, vol. 162, 67) using arachidonic acid 0.25 mM as aggrega- ting agent.
The inhibition activity was evaluated as ED50 (in mM) , i.e. the dose which antagonizes 50% of the aggregat¬ ing effect of arachidonic acid.
The thromboxane A2 production was measured by a bioassay test according to Moncada et al. (Moncada S., Ferreira S.H., Vane J.R. - Adv. Prost. & Thromboxanes Res. - Frolich J.C. Ed., Vol. 5, 211, 1978 - Raven Press). At scheduled times after the addition of arachidonic acid, 200 ul of P.R.P. was bioassayed for the TXA2 production and prostaglandin-like activity, on a tissue 'sequence (cascade), composed of a spiral strip of rabbit aorta and a stomach fundus strip of rat.
The inhibition activity of the tested compounds on TXA2 production was evaluated as ED50 (in M) , i.e. the concentration able to decrease the contracturant effects of TXA2 on tissues.
The tested compounds were dissolved in Tween 80 and added to the P.R.P. at increasing concentrations, until the determination of the ED50 was achieved. In- Table 3, as not limiting example, the results obtained using some of the compounds of the invention are reported.
TABLE 3 Inhibition (ED50, in M) on arachidonic acid induced:
Figure imgf000018_0001
ANTIINFLAMMATORY ACTIVITY ON NON-IMMUNE AND IMMUNE INFLAM¬ MATION 1 - Carrageenin induced pleurisy in rats (non-immune in¬ flammation)
The test has been performed according to Di Rosa et al. (Di Rosa M. , Giround J.P., Willoughby D.A. - J. Path. Bact., vol. 104, 15, 1971). A 1% solution (0.15 ml) of carrageenin in 0.9% NaCl, was injected into the pleural cavity of Sprague-Dawley rats, weighing about 250 g. Six hours later, the animals were sacrificed, the pleural exudate volumes were measured and the leukocytes total number was counted by a micro- cell-counter, being the cavity rinsed by 0.5 ml of a sali- ne medium.
The % inhibition of leukocytes total number was calcu¬ lated versus control animals. The assayed compounds were administered orally, 1 mM/kg, 30' before the carrageenin injection in the pleural cavity. In Table IV, as not limi¬ ting example, the results obtained with some of the compo¬ unds of the invention are reported.
TABLE 4 % Inhibition on:
Figure imgf000019_0001
- continued - TABLE 4 (follows)
Figure imgf000020_0001
- continued - TABLE 4 ( follows )
Figure imgf000021_0001
(*) L-Leucyl-5-amino-salicylic, described in Ger. Offen. ' 2,919,545;
(**) T-L-Glutam"yl-5-amino-salicylic, described in Ger.
Offen. 2,920,292; (***) Aceto acetyl-5-amino-salicylic, described in Japan Kokai 78-9651.
2 - Reserve passive Arthus reaction in rat paws (Immune inflammation)
The assay has been performed according to Gemmel et al. (Gemmel D.K. Cottney J., Lewis A.J. - Agents Actions, vol. 9, 107, 1979). 1 Ml of a rabbit anti-bovine-albumin serum (freeze-dried antibodies, dissolved in 2 ml of 0.9% NaCl) was injected into the caudal vena of Sprague-Dawley male rats.
30' Later, 0.025 mg of bovine albumin (in 0.1 ml sali¬ ne) was injected in the subplantar paw. The volume of the paw was measured 5 hours later, by a mercury plethysmome- ter. The tested compounds were orally administered 3 hours before the bovine albumin treatment. The % inhibition of the rat foot volume increase was calculated in confront to the increase of the foot volume of untreated animals. The results obtained with some of the compounds of the inven¬ tion are reported in Table 5.
TABLE 5
Figure imgf000023_0001
- continued - TABLE 5 ( follows )
Figure imgf000024_0001
Na-5-ASA: 5-amino salicylic acid sodium salt
The numbers in parenthesis indicate the administered dose in mg/kg.
The orally administrations are equivalent to one mM/kg for each tested compound. 3 - Acetic acid bowel inflammation in rats (non immune bowel inflammation)
The assay has been performed according to Sharon (Sharon P., Stenson W.F. - Gastroenterology, vol. 88, 55, 1985) .
Considering the nature of the assay, the test was performed mainly on the compounds of * the invention not well absorbed, according to the results, obtained in the previous tests.* It should be noted, however, that all the claimed derivatives can be usefully applied in the therapy of the bowel inflammation and in the Crohn' disease.
The results are reported in the following Table 6.
The administered doses (via intra-bowel, during the bowel ligature and the local injection of the acetic acid) were 0.5 mM/kg, for all the tested compounds, dispersed" in carboxymethylcellulose. The % reduction of the ulceration index has been calculated versus untreated animals.
TABLE 6
Compounds % Reduction of the ulceration index
2 -36
2a -51
14 -38
14a -58
19 -42
19a -65
20 -42
20a • -65 Acute toxicity
The compounds of Table 1 have been subjected to the acute toxicity test in mice, by the oral route, in carbo¬ xymethylcellulose suspensions. All the LD proved to be higher than 1600 mg/kg.
The present invention refers also to all the indu¬ strial applicable aspects connected with the use of the compounds I and of the corresponding free acids as thera¬ peutic agents. An essential aspect, of the invention is therefore provided by pharmaceutical compositions contain¬ ing, as the active principle, predetermined and therapeu- tically effective amounts of at least one of the above compounds in addition to conventional excipients and/or carriers. The compositions of the Invention can be administered by the oral, parenteral, rectal or topical route, for instance in form of tablets, capsules, syrups, sachets, solutions, vials, bottles, suppositories.
The doses will be dependent on the patient's weight, age and conditions and will be anyhow ranging from 50 to 1000 mg, from 1 to 4 times a day.

Claims

COO ,Θ H©
Figure imgf000027_0001
wherein:
B Θ^ i •s the i •midazolium or C- or N-substituted imidazolium cation, lysine or similar basic aminoacids or methyl- glucamine; R represents:
- hydrogen or a linear C -C alkyl chain, , optionally substituted by one or more chlorine or fluorine atoms, free, etherified or esterified hydroxy groups, carboxy, carboxyalkyl, aminocarbonyl or N-substituted aminocarbo- nyl groups, one or more of the -CH - groups being optio¬ nally substituted by keto groups;
- a chain of formula:
Figure imgf000027_0002
wherein n is an integer from 1 to 10 and R and R , which may be the same or different, are H, halogens, -OR or COOR groups wherein R is hydrogen or C -C lower alkyl; - a chain of formula: -(CH ) -Het 2 m wherein m is an integer from 0 to 20 and Het is an op¬ tionally substituted 5- or 6-membered heterocyclic group containing one or more N, 0 or S atoms such as pyrrole, pyridine, furan, pyran, thiophene, oxazole, isoxazole, imidazole, pyrazole, thiazole groups; a chain of formula:
N N-(CH„) -CO-
\_____/ 2 P wherein p is an integer from 0 to 16; a chain of formula:
Figure imgf000028_0001
wherein q is an integer from 1 to 16;
- an aryl or aralkyl residue such as phenyl; phenyl sub¬ stituted by one or more fluorine or chlorine atoms, fluoroalkyl, alkoxy, alkoxycarbonyl, C -C lower alkyl, amino, dialkylamino, hydroxy, cyano groups or by groups of formula NHCOR wherein R has the above defined mean¬ ings; diphenyl; naphtyl groups;
- a chain of formula:
Figure imgf000028_0002
wherein m has the above defined meanings and R is hy¬ drogen or a linear or branched, saturated or unsaturat- ed, c ~C alkyl group; - a chain of the formula:
Figure imgf000029_0001
wherein R , R and R , which may be the same or diffe- 5 6 7 rent, are H, OR (R having the above defined meanings), NH , NHCOR , chlorine or fluorine atoms, fluoroalkyl groups; - a chain of formula:
Figure imgf000029_0002
wherein R is hydrogen, lower alkyl, fluorine or fluoro- 8 alkyl; * " ■ - a linear or branched chain of the formula:
*
-(CH_j -X-CH-(CH-) ,-Y- 2 n I 2 n'
wherein R and n have the above defined meanings, n1 is an integer from 1 to 10 and X and Y are an oxygen, ni- trogen, sulphur atom or a CH group;
- a chain of formula:
-(CH2)r-S-R3 wherein r is an integer from 1 to 3 and R has the above defined meanings; - an aminoacid residue, namely -leucyl, Of or Y-L-glu- tamyl- in a free form or protected with the conventional amine protecting group, such as BOC;
- an Arg-Pro-D(Phe) chain or the like;
- an uronic residues of formula:
Figure imgf000030_0001
2. Compounds according to claim 1 wherein B is imidazo lium or 2-aminoimidazolium.
3. A compound according to claim 1 wherein B is the imidazolium residue and the anionic component is selected in the group consisting of: - 2-hydroxy-5-(2, 4-dichlorobenzoyl)amino-benzoic acid;
- 2-hydroxy-5-hexadecanoyl-amino-benzoic acid;
- 2-hydroxy-5-isovaleroyl-amino-benzoic acid;
- 2-hydroxy-5-cyclohexylacetyl-amino-benzoic acid;
- 2-hydroxy-5-succinoyl-amino-benzoic acid; * _ - 2-hydroxy-5-benzoyl-amino-benzoic acid;
- 2-hydroxy-5-salicyloyl-amino-benzoic acid;
- 2-hydroxy-5-/4-( 2 ' , 4 ' -difluorophenyl) salicyloyl-amino/- benzoic acid;
- 2-hydroxy-5-( -ethoxycarbonyl)glycyl-amino-benzoic acid; - 2-hydroxy-5*-/( 6-ethoxycarbonylamino)capropylamino/-ben- zoic acid;
- 2-hydroxy-5-(N-ethoxycarbonylglutamoylamino)-benzoic acid;
- 2-hydroxy-5-glucuronyl-amino-benzoic acid; - 2-hydroxy-5-formyl-amino-benzoic acid;
- 2-hydroxy-5-stearoyl-amino-benzoic acid;
- 2-hydroxy-5-( 4-methoxy)benzoyl'-amino-benzoic acid;
- 2-hydroxy-5-( 4-eptyloxy)benzoyl-amino-benzoic acid;
- 2-hydroxy-5-( 4-fluoro)benzoyl-amino-benzoic acid; - 2-hydroxy-5-acetyl-amino-benzoic acid; - 2-hydroxy-5-linoleyl-amino-benzoic acid;
- 2-hydroxy-5-arachidyl-amino-benzoic acid;
- 2-hydroxy-5-arachidonyl-amino-benzoic acid;
- 2-hydroxy-5-( 2, 6-difluoro)benzoyl-amino-benzoic acid; - 2-hydroxy-5-( 3 , 5-difluoro)benzoyl-amino-benzoic acid;
- 2-hydroxy-5-( 4-cyclohexyl-butanoyl)-amino-benzoic acid;
- 2-hydroxy-5-( 2-( 3-pyridyl)-acetyl)-amino-benzoic acid;
- 2-hydroxy-5-( 4-phenyl-benzoyl)-amino-benzoic acid;
- 2-hydroxy-5-(m-trifluoromethyl-cinnamoyl) -amino-benzoic acid;
- 2-hydroxy-5-( 8-( 1-imidazolyl) -octanoyl)-amino-benzoic acid
- L-leucyl-5-amino-salicylic acid;
- 7"-L-glutamyl-5-amino-salicylic acid; - aceto acetyl-5-amino-salicylic acid.
4. As a novel compound, a compound selected in the group consisting of:
- 2-hydroxy-5-( 4-cyclohexyl-butanoyl)-amino-benzoic acid;
- 2-hydroxy-5-( 2-( 3-pyridyl)-acetyl)-amino-benzoic acid; - 2-hydroxy-5-( 4-phenyl-benzoyl)-amino-benzoic acid;
- 2-hydroxy-5-(m-trifluoromethyl-cinnamoyl)-amino-benzoic acid;
- 2-hydroxy-5-( 8-( 1-imidazolyl)-octanoyl)-amino-benzoic acid.
5. A process for the preparation of compounds of formula I characterized in that the 2-hydroxy-5-amino-benzoic acid is reacted with acyl chlorides or anhydrides of acids having formula RCOOH, wherein R has the above defined meanings, and that the obtained N,0-diacyl derivatives are hydrolyzed in the presence of imidazole and subsequently reacted with the base B.
6. Pharmaceutical compositions endowed with antiinflam- matory, antiaggregant, antithrombotic activity containing as the active principle one or more of the compounds of cla ims 1-4.
7. Pharmaceutical compositions endowed with antiinflam- matory, antiaggregant, antithrombotic activity contain¬ ing as the active principle at least a compound of formula:
Figure imgf000032_0001
wherein R has the* above defined meanings or of pharmaceuti cally acceptable salts thereof.
8. A method of treatment of inflammatory, thrombotic or hyperaggregating conditions in a living subject characteri¬ zed by administering to said living subject a composition of claims 6-7.
PCT/EP1985/000645 1984-11-29 1985-11-26 Amino-salicylic acid derivatives and pharmaceutical compositions WO1986003199A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK346486A DK346486A (en) 1984-11-29 1986-07-21 AMINOSALICYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENTS
KR1019860700507A KR870700608A (en) 1984-11-29 1986-07-28 Amino-salicylic acid derivatives and pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT23799A/84 1984-11-29
IT23799/84A IT1196348B (en) 1984-11-29 1984-11-29 COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY

Publications (1)

Publication Number Publication Date
WO1986003199A1 true WO1986003199A1 (en) 1986-06-05

Family

ID=11210091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1985/000645 WO1986003199A1 (en) 1984-11-29 1985-11-26 Amino-salicylic acid derivatives and pharmaceutical compositions

Country Status (12)

Country Link
EP (1) EP0236329A1 (en)
JP (1) JPS62501703A (en)
KR (1) KR870700608A (en)
CN (1) CN85109554A (en)
AU (1) AU5231186A (en)
DK (1) DK346486A (en)
ES (1) ES8701717A1 (en)
GR (1) GR852834B (en)
IT (1) IT1196348B (en)
PT (1) PT81566B (en)
WO (1) WO1986003199A1 (en)
ZA (1) ZA859035B (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003412A2 (en) * 1990-08-13 1992-03-05 Rhone-Poulenc Rorer Limited Benzamide derivatives
WO1992003408A1 (en) * 1990-08-13 1992-03-05 Rhone-Poulenc Rorer Limited Benzanilide derivatives and their use as anti-antherosclerotic agents
WO1992004369A1 (en) * 1990-09-12 1992-03-19 Depha Team S.R.L. 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
EP0760241A1 (en) * 1995-09-01 1997-03-05 Synthelabo Use of sulfasalazine and its active metabolite for the manufacture of a medicament for the treatment of venous insufficiency and venous ulcers
WO2001079153A1 (en) * 2000-04-19 2001-10-25 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
US6573402B1 (en) 2000-04-20 2003-06-03 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
KR100668111B1 (en) 2005-07-28 2007-01-12 (주)에스에이치제약 New aminosalicylic acid analogs, it's pharmaceutically acceptable salts and their preparations
US7189878B2 (en) 2002-06-19 2007-03-13 Neurotech Co., Ltd. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
EP2201946A1 (en) * 2007-10-23 2010-06-30 Institute of Medicinal Molecular Design, Inc. Pai-1 production inhibitor
WO2010090494A3 (en) * 2009-02-09 2011-01-06 주식회사 뉴로테크 Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
US8455470B2 (en) 2006-04-13 2013-06-04 Neurotech Pharmaceuticals Co., Ltd Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
US8686185B2 (en) 2007-11-12 2014-04-01 Neurotech Pharmaceuticals Co., Ltd. Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
WO2014070859A1 (en) * 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US9139516B2 (en) 2008-07-08 2015-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
US9238077B2 (en) 2009-09-01 2016-01-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2020136441A1 (en) * 2018-12-28 2020-07-02 Gnt Pharma Co., Ltd. Compositions and methods for treating neurodegenerative disorders

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60114724T2 (en) * 2000-07-18 2006-06-01 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Blood flow improvers and preparations for the prevention or cure of thrombosis
EP1225449B1 (en) 2001-01-19 2008-10-22 Apex Biotechnology Corporation Non-enzymatic disposable electrode strip comprising a surfactant for detecting uric acid or hemoglobin; method for producing the same and its use
CN100422721C (en) * 2006-05-26 2008-10-01 南京大学 Aluminium ion investigating method using glycosyl naphthol
JP6202287B2 (en) * 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of inflammatory bowel disease
CN111116395B (en) * 2019-12-27 2023-04-07 湖北工业大学 Multi-iodo aromatic acid compound and application thereof in resisting adenovirus 7

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4546M (en) * 1964-06-09 1966-11-02
DE2031227A1 (en) * 1969-06-25 1971-01-07 Merck & Co , Ine , Rahway, N J (V St A) New substituted Sahcylsauren and process for their production
FR2214476A1 (en) * 1973-01-18 1974-08-19 Kissei Pharmaceutical
JPS54125632A (en) * 1978-03-20 1979-09-29 Hisamitsu Pharmaceut Co Inc Novel salicylic acid derivative
EP0124791A1 (en) * 1983-05-06 1984-11-14 American Cyanamid Company Aralkanamidophenyl compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4546M (en) * 1964-06-09 1966-11-02
DE2031227A1 (en) * 1969-06-25 1971-01-07 Merck & Co , Ine , Rahway, N J (V St A) New substituted Sahcylsauren and process for their production
FR2214476A1 (en) * 1973-01-18 1974-08-19 Kissei Pharmaceutical
JPS54125632A (en) * 1978-03-20 1979-09-29 Hisamitsu Pharmaceut Co Inc Novel salicylic acid derivative
EP0124791A1 (en) * 1983-05-06 1984-11-14 American Cyanamid Company Aralkanamidophenyl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 92, No. 19, 12 May 1980 (Columbus, Ohio, US) see page 578, Abstract No. 163724c, & JP, A, 79125632 (Hisamitsu Pharmaceutical Co., Inc.) 29 September 1979 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003408A1 (en) * 1990-08-13 1992-03-05 Rhone-Poulenc Rorer Limited Benzanilide derivatives and their use as anti-antherosclerotic agents
WO1992003412A3 (en) * 1990-08-13 1992-04-30 Rhone Poulenc Rorer Ltd Benzamide derivatives
WO1992003412A2 (en) * 1990-08-13 1992-03-05 Rhone-Poulenc Rorer Limited Benzamide derivatives
US5424292A (en) * 1990-09-12 1995-06-13 Depha Team S.R.L. 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases
WO1992004369A1 (en) * 1990-09-12 1992-03-19 Depha Team S.R.L. 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases
US5441975A (en) * 1991-08-22 1995-08-15 Warner-Lambert Company Pyrazolo-substituted alkyl amide acat inhibitors
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5646170A (en) * 1991-08-22 1997-07-08 Warner-Lambert Company Tetrazole alkyl amide acat inhibitors
US5693657A (en) * 1991-08-22 1997-12-02 Warner-Lambert Company Heterocyclic-substituted alkyl amide acat inhibitors
EP0760241A1 (en) * 1995-09-01 1997-03-05 Synthelabo Use of sulfasalazine and its active metabolite for the manufacture of a medicament for the treatment of venous insufficiency and venous ulcers
FR2738150A1 (en) * 1995-09-01 1997-03-07 Synthelabo USE OF SULPHASALAZINE AND ITS METABOLITES FOR THE MANUFACTURE OF A MEDICAMENT USEFUL IN THE TREATMENT OF VENOUS INSUFFICIENCY AND VENOUS ULCERS
US5668123A (en) * 1995-09-01 1997-09-16 Synthelabo Method of maintaining remission from venous ulcers with sulphasalazine and its metabolite
WO2001079153A1 (en) * 2000-04-19 2001-10-25 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US7750045B2 (en) 2000-04-20 2010-07-06 Neurotech Pharmaceuticals Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US6964982B2 (en) 2000-04-20 2005-11-15 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US8211878B2 (en) 2000-04-20 2012-07-03 Neurotech Pharmaceuticals Co., Ltd. Method for reducing neuronal death in nervous system injuries resulting from amyotrophic lateral sclerosis
US8211877B2 (en) 2000-04-20 2012-07-03 Neurotech Pharmaceuticals Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US6573402B1 (en) 2000-04-20 2003-06-03 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
US7189878B2 (en) 2002-06-19 2007-03-13 Neurotech Co., Ltd. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
US7511074B2 (en) 2002-06-19 2009-03-31 Amkor Pharma, Inc. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
US7371896B2 (en) 2002-06-19 2008-05-13 Amkor Pharma, Inc. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
US7319160B2 (en) 2002-06-19 2008-01-15 Amkor Pharma, Inc. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
KR100668111B1 (en) 2005-07-28 2007-01-12 (주)에스에이치제약 New aminosalicylic acid analogs, it's pharmaceutically acceptable salts and their preparations
US8598383B2 (en) 2006-04-13 2013-12-03 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
US8455470B2 (en) 2006-04-13 2013-06-04 Neurotech Pharmaceuticals Co., Ltd Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
EP2201946A1 (en) * 2007-10-23 2010-06-30 Institute of Medicinal Molecular Design, Inc. Pai-1 production inhibitor
EP2201946A4 (en) * 2007-10-23 2012-01-25 Inst Med Molecular Design Inc Pai-1 production inhibitor
US8686185B2 (en) 2007-11-12 2014-04-01 Neurotech Pharmaceuticals Co., Ltd. Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
US9272984B2 (en) 2008-07-08 2016-03-01 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US9708245B2 (en) 2008-07-08 2017-07-18 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US9139516B2 (en) 2008-07-08 2015-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
US9458094B2 (en) 2008-07-08 2016-10-04 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
WO2010090494A3 (en) * 2009-02-09 2011-01-06 주식회사 뉴로테크 Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
CN102316863A (en) * 2009-02-09 2012-01-11 纽若泰克制药株式会社 The medical usage of 5-benzylamino salicyclic acid derivatives or its salt
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
US9238077B2 (en) 2009-09-01 2016-01-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
US9486534B2 (en) 2009-09-01 2016-11-08 Catabasis Pharmaceuticals, Inc. Niacin conjugated fatty acid mixtures and their uses
USRE46605E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
US20150259366A1 (en) * 2012-10-30 2015-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
WO2014070859A1 (en) * 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
US9822135B2 (en) * 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
US10494389B2 (en) 2012-10-30 2019-12-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
US10954258B2 (en) 2012-10-30 2021-03-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
WO2020136441A1 (en) * 2018-12-28 2020-07-02 Gnt Pharma Co., Ltd. Compositions and methods for treating neurodegenerative disorders

Also Published As

Publication number Publication date
AU5231186A (en) 1986-06-18
PT81566B (en) 1987-04-07
DK346486D0 (en) 1986-07-21
ZA859035B (en) 1986-08-27
ES549359A0 (en) 1986-12-01
ES8701717A1 (en) 1986-12-01
EP0236329A1 (en) 1987-09-16
DK346486A (en) 1986-07-21
CN85109554A (en) 1986-07-23
PT81566A (en) 1985-12-01
KR870700608A (en) 1987-12-30
IT8423799A0 (en) 1984-11-29
GR852834B (en) 1986-03-27
IT1196348B (en) 1988-11-16
JPS62501703A (en) 1987-07-09

Similar Documents

Publication Publication Date Title
WO1986003199A1 (en) Amino-salicylic acid derivatives and pharmaceutical compositions
US4443475A (en) Amides of acyl-carnitines, process for preparing same and pharmaceutical compositions containing such amides
US5912260A (en) Gastrin and CCK antagonists
JPS595196A (en) Esters of phosphinylalkanoyl-substituted prolines
CA1334972C (en) Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds
JPS59139357A (en) Amidine derivative
NL8002828A (en) 2- (MERCAPTO-1-OXOALKYL) -1,2,3,4-TETRAHYDROISOQUINOLINE -3-CARBONIC ACIDS AND THEIR DERIVATIVES.
CZ287768B6 (en) Amides of sulfonamidocarbonylpyridine-2-carboxylic acids, process of their preparation and medicaments based thereon
NL8903132A (en) CAPSAICIN DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICS.
US4096256A (en) 7-Acyl-3-(ureidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them, and methods of treating bacterial infections using them
US4496735A (en) Certain pyridyloxy-or-thio-phenyl propenoic acid derivatives
US4404214A (en) 2-Pyridinecarboxamide derivatives compositions containing same and method of using same
JPS63216872A (en) Heterocyclic compound
US4510142A (en) Derivatives of biphenyl alkyl carboxylates and their use as medicaments
FI76324C (en) Process for the preparation of novel, therapeutically useful isoquinoline derivatives
IE60205B1 (en) Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
CZ322092A3 (en) N-(alpha-substituted pyridinyl)carbonyl dipeptides, process of their preparation and pharmaceutical compositions based thereon
US4277496A (en) Methods of treating mammals suffering from inflammation and pain
US4143143A (en) Substituted imidazo[5,1-a]isoquinolines
US4478843A (en) 5-Phenyltetrazoles and their use as salidiuretics
US4273777A (en) Methods of treating mammals suffering from inflammation and pain
US5364873A (en) Pyridine-2,4- and dicarboxylic acid derivatives, the use thereof and pharmaceutical composition based on these compounds
FI68622C (en) FOERFARANDE FOER FRAMSTAELLNING AV INDOLAETTIKSYRADERIVAT
US4311699A (en) Aminoacid derivatives of cephalosporin compounds
FI77022C (en) Process for the preparation of novel therapeutically useful pyrroleic acid derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR DK FI HU JP KP KR NO RO SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1986900097

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986900097

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986900097

Country of ref document: EP